[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617800":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":31,"locations":41,"responsibleParty":62,"collaborators":31,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":31,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":31,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":44,"whyStopped":31,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Beni-Suef University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Somatropin group","EXPERIMENTAL","Somatropin (4IU for 1 month) 1 S.C injection every 3 days for at least 1 month plus, folic acid 400mcg\u002Fday",[13],"Drug: Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.",{"label":15,"type":10,"description":16,"interventionNames":17},"dehydroepiandrosterone","dehydroepiandrosterone 50 mg twice per day for 12 weeks plus folic acid 400mcg per day",[18],"Drug: DHEA plus folic acid 400mcg per day",{"label":20,"type":21,"description":22,"interventionNames":23},"Standard care","ACTIVE_COMPARATOR","Patients will receive standard care will receive folic acid 400 mcg per day",[24],"Dietary Supplement: control group",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.","Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"DHEA plus folic acid 400mcg per day","Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day",[15],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":31},"DIETARY_SUPPLEMENT","control group","Patients will receive folic acid 400 mcg per day",[20],[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Beni-Suef University Hospital","RECRUITING","Banī Suwayf","Beni Suweif Governorate","62521","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.09785,29.07441,{"lat":54,"lon":53},[57],{"name":58,"role":59,"phone":60,"phoneExt":31,"email":61},"Marwa O. Elgendy, Associate professor","CONTACT","00201021941935","amal.emam@yahoo.com",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Hasnaa Osama","Lecturer of Clinical Pharmacy, Beni-Suef University","100617800","phase-2-growth-hormone-and-dehydroepiandrosterone-role-in-vitro-fertilization-100617800",false,"NCT07323329","Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization","Growth Hormone and Dehydroepiandrosterone Effect on Poor Ovarian Reserve Patients During in Vitro Fertilization","Inclusion Criteria:\n\nAt least two of the following three criteria had to be present after maximal stimulation:\n\n1. Advanced maternal age (\\>40 years) or any other risk factor for Poor Ovarian Response (POR).\n2. ≤3 oocytes with a conventional stimulation protocol).\n3. An abnormal ovarian reserve test \\[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng\u002Fml\\].\n\nExclusion Criteria:\n\n1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction.\n2. Any pelvic pathology such as hydrosalpinx, uterine anomaly.\n3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia","FEMALE","18 Years","35 Years",{"count":77,"type":78},165,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE2","PHASE3","The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.\n\nThe main question it aims to answer is:\n\nWhich intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.",[85,86],"Infertility","Infertility (IVF Patients)",[88,85,89,90],"Growth hormone","IVF patients","Ovarian reserve","2025-12-31",{"date":93,"type":94},"2026-01-07","ACTUAL",{"date":96,"type":94},"2025-10-10",{"date":98,"type":78},"2026-11-12",{"name":5,"class":6},1]